The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10820 malaria professionals are enjoying the free benefits of MalariaWorld today

clinical trial

Predicting the public health impact of a malaria transmission-blocking vaccine

March 10, 2021 - 13:16 -- Open Access
Author(s): 
Challenger JD, Olivera Mesa D, Da DF, Yerbanga RS, Lefèvre T, Cohuet A, Churcher TS
Reference: 
Nat Commun. 2021 Mar 8;12(1):1494

Transmission-blocking vaccines that interrupt malaria transmission from humans to mosquitoes are being tested in early clinical trials. The activity of such a vaccine is commonly evaluated using membrane-feeding assays. Understanding the field efficacy of such a vaccine requires knowledge of how heavily infected wild, naturally blood-fed mosquitoes are, as this indicates how difficult it will be to block transmission.

A Systematic Literature Review of Microscopy Methods Reported in Malaria Clinical Trials

December 23, 2020 - 08:50 -- Open Access
Author(s): 
Das D, Dahal P, Dhorda M, Citarella BW, Kennon K, Stepniewska K, Felger I, Chappuis F, Guerin PJ
Reference: 
Am J Trop Med Hyg. 2020 Dec 21

Microscopy of stained blood films is essential for the diagnosis of malaria, differentiation of parasite species, and estimation of parasite density performed for assessments of antimalarial drug efficacy. The accuracy and comparability of these measures over time and space are vital to discern the emergence or spread of antimalarial drug resistance. Although evidence-based guidelines for malaria microscopy methods exist, the age-old microscopy techniques for parasitological assessments are subject to considerable methodological variations.

Enhancing durability of CIS43 monoclonal antibody by Fc mutation or AAV delivery for malaria prevention

December 23, 2020 - 08:35 -- Open Access
Author(s): 
Kielau Kisalu N, Da Silva Pereira L, Ernste KJ, Flores-Garcia Y, Idris AH, Asokan M, Dillon M, MacDonald S, Shi W, Chen X, Pegu A, Schön A, Zavala F, Balazs AB, Francica JR, Seder RA
Reference: 
JCI Insight. 2020 Dec 17:143958

CIS43 is a potent neutralizing human monoclonal antibody (mAb) that targets a highly conserved 'junctional' epitope in the Plasmodium falciparum (Pf) circumsporozoite protein (PfCSP). Enhancing the durability of CIS43 in vivo will be important for clinical translation. Here, two approaches were used to improve the durability of CIS43 in vivo while maintaining potent neutralization.

NOT Open Access | First-in-human clinical trial to assess safety, tolerability and pharmacokinetics of P218, a novel candidate for malaria chemoprotection

January 14, 2020 - 09:44 -- NOT Open Access
Author(s): 
Chughlay MF, Rossignol E, Donini C, El Gaaloul M, Lorch U, Coates S, Langdon G, Hammond T, Möhrle J, Chalon S
Reference: 
Br J Clin Pharmacol. 2020 Jan 11

This first‐in‐human clinical trial of P218, a novel dihydrofolate reductase inhibitor antimalarial candidate, assessed safety, tolerability, pharmacokinetics and food effect in healthy subjects.

Monitoring of efficacy, tolerability and safety of artemether–lumefantrine and artesunate–amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Lambaréné, Gabon: an open-label clinical trial

December 17, 2019 - 16:46 -- Open Access
Author(s): 
Bayode R. Adegbite, Jean R. Edoa, Ayola A. Adegnika, et al.
Reference: 
Malaria Journal 2019 18:424, 16 December 2019

Malaria remains a major public health problem, affecting mainly low-and middle-income countries. The management of this parasitic disease is challenged by ever increasing drug resistance. This study, investigated the therapeutic efficacy, tolerability and safety of artemether–lumefantrine (AL) and artesunate–amodiaquine (AS–AQ), used as first-line drugs to treat uncomplicated malaria in Lambaréné, Gabon.

Job: BOHEMIA Clinical Trial Clinical Trial investigator, Mopeia Site (Mozambique)

November 21, 2019 - 16:19 -- MalariaWorld Jobs

Job title: Clinical Trial Investigator for Mopeia site (Mozambique)
Reports to: Mozambique BOHEMIA National Principal Investigator and the ISGlobal BOHEMIA Chief Scientific Officer

Harmonization study between three laboratories for expression of malaria vaccine clinical trial IgG antibody ELISA data in µg/mL

September 14, 2019 - 15:20 -- Open Access
Author(s): 
Geneviève M. Labbé, Kazutoyo Miura, Simon J. Draper, et al.
Reference: 
Malaria Journal 2019 18:300, 2 September 2019

The ability to report vaccine-induced IgG responses in terms of µg/mL, as opposed arbitrary units (AU), enables a more informed interpretation of the magnitude of the immune response, and better comparison between vaccines targeting different antigens. However, these interpretations rely on the accuracy of the methodology, which is used to generate ELISA data in µg/mL. In a previous clinical trial of a vaccine targeting the apical membrane antigen 1 (AMA1) from Plasmodium falciparum, three laboratories (Oxford, NIH and WRAIR) reported ELISA data in µg/mL that were correlated but not concordant. This current study sought to harmonize the methodology used to generate a conversion factor (CF) for ELISA analysis of human anti-AMA1 IgG responses across the three laboratories.

Subscribe to RSS - clinical trial